Novel heteroary1 derivatives and their use as medicaments

ABSTRACT

The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.

FIELD OF THE INVENTION

[0001] The invention relates to novel heteroaryl derivatives to their preparation and to their use as medicaments, in particular for treating tumors.

DESCRIPTION OF INVENTION

[0002] According to one aspect of the present invention, novel pyridine derivatives are provided of formula 1

[0003] wherein

[0004] R, R₁, R₂, R₃ can be attached to any of the pyridine carbon atoms C₂₋₆, and are the same or different and independently of one another are hydrogen, hydroxyl straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, straight-chain or branched C₁₋₈ alkylcarbonyl, suitably acetyl, straight-chain or branched C₁₋₈ alkoxy, halogen, aryl-C₁₋₈ alkoxy, suitably benzyloxy or phenylethyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, C₁₋₈ alkoxycarbonylamino, C₁₋₆ alkoxycarbonylamino-C₁₋₈ alkyl, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, carboxyl, C₁₋₈ alkoxycarbonyl, C₁₋₄ alkyl which is substituted by one or more fluorine atoms, suitably the trifluoromethyl group, carboxy-C₁₋₈ alkyl or C₁₋₈ alkoxycarbonyl-C₁₋₆ alkyl C₂₋₆ alkenyl, suitably allyl, C₂₋₆ alkynyl, suitably ethynyl or propargyl, straight-chain or branched cyano-C₁₋₆ alkyl, suitably cyanomethyl, aryl, where the aryl radical may be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of halogen, straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, suitably tert-butoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, where additionally R and R₁ and/or R₂ and R₃ may form a fused aromatic 6-membered ring with the pyridine ring forming a quinoline or acridine ring which can be substituted at any C atom ring position by the radicals R, R₁, R₂ and R₃ having the meanings mentioned above;

[0005] Z is oxygen or sulfur, where the radical

[0006]  substituted on the pyridine heterocycle can be attached to C atoms C₂-C₆ of the pyridine ring;

[0007] P, Q are independently of one another oxygen or in each case two hydrogen atoms as in —CH₂—;

[0008] X is nitrogen or C-R₅, where R₅ is hydrogen or C₁₋₆ alkyl;

[0009] n,m are independently of one another a cardinal number between 0 and 3, with the proviso that in the case when n is 0, X is a CR₅R₆ group where R₅ and R₆ are independently of one another hydrogen or C₁₋₆ alkyl and that the nitrogen atom adjacent to the C═Z group is substituted by a hydrogen atom or a C₁₋₆ alkyl group;

[0010] R₄ a straight-chain or branched C₁₋₂₀ alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or can be substituted at the same or different C atoms by one, two or more aryl, heteroaryl, halogen, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino, cyano, —C═NH (NH₂), or di-C₁₋₄ alkylamino; a C₆₋₁₄ aryl radical, carboxy, C₁₋₄ alkoxycarbonyl, C₆₋₁₄ aryl-C₁₋₄ alkyl radical or a C₂₋₁₀ heteroaryl or C₂₋₁₀ heteroaryl-C₁₋₄ alkyl radical which contains one or more heteroatoms of N, O or S, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and where the C₆₋₁₄ aryl or C₂₋₁₀ heteroaryl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₄ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₄ alkyl which is substituted by one or more fluorine atoms, suitably trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups, suitably by a methylene group, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which for its part can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl;

[0011] and their structural isomers and stereoisomers, particularly tautomers, diastereomers and enantiomers, and their pharmaceutically acceptable salts, particularly acid addition salts, are provided.

[0012] Thus, for example, the compounds of formula (1) according to the present invention which have one or more centers of chirality and which are present as racemates can be separated by methods known per se into their optical isomers, i.e. enantiomers or diastereomers. The separation can be carried out by column separation on chiral phases or by recrystallization from an optically active solvent or using an optically active acid or base or by derivatization with an optically active reagent, such as, for example, an optically active alcohol, and subsequent removal of the radical.

[0013] Furthermore, the pyridine derivatives of formula (1) of the present invention can be converted into their salts with inorganic or organic acids, in particular, for pharmaceutical use, into their pharmaceutically acceptable salts. Acids which are suitable for this purpose include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, acetic acid, tartaric acid, malic acid, embonic acid, malonic acid, trifluoroacetic acid or maleic acid.

[0014] Moreover, the compounds of formula (1) of the present invention can, if they contain a sufficiently acidic group, such as a carboxyl group, be converted into their salts with inorganic or organic bases, particularly for pharmaceutical use, into their pharmaceutically acceptable salts. Bases which are suitable for this purpose include sodium hydroxide, potassium hydroxide, calcium hydroxide, lysine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

[0015] According to a suitable embodiment, pyridine derivatives of formula 1 are provided in which R, R1, R2, R3, X, Z, P, Q, n and m have the meanings given above

[0016] Y is a substituent group of the same or different substituents of C₁₋₆ alkyl, halogen, nitro, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, hydroxyl, C₁₋₆ alkoxy, benzyloxy, carboxyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkyl mono- or polysubstituted with fluorine, suitably trifluoromethyl, C₆₋₁₀ aryl, and C₆₋₁₀ aryl-C₁₋₆ alkyl, and

[0017] R₄ is a straight-chain or branched C₁₋₂₀ alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or substituted on the same or different C atoms by one, two or more aryl, heteroaryl, halogen, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino;

[0018] a phenyl ring or a naphthyl ring, each of which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, suitably trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups, suitably a methylene group, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl;

[0019] a 2-, 4-, 5- or 6-pyrimidinyl radical, or a 2-, 4-, 5- or 6-pyrimidinyl -C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by identidal or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, 5- or 6-pyrimidinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0020] a 3-, 4-, 5- or 6-pyridazinyl radical, or a 3-, 4-, 5- or 6-pyridazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 3-, 4-, 5- or 6-pyridazinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0021] a 2-, 3-, 5- or 6-pyrazinyl radical, or a 2-, 3-, 5- or 6-pyrazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by identidal or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 5- or 6-pyrazinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0022] a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical, or a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0023] a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical, or a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0024] a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical, or a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0025] a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical, or a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical can be unsubstituted or mono- to pentasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0026] a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical, or a 2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical can be unsubstituted or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0027] a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical, or a 1-, 3-, 4-, 5-, 6-, 7-or 8-isoquinolyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical can be unsubstituted or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0028] a 2-, 6-, 8- or 9-[9H]-purinyl radical, or a 2-, 6-, 8- or 9-[9H]-purinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 6-, 8- or 9-[9H]-purinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0029] a 2-, 6-, 7- or 8-[7H]-purinyl radical, or a 2-, 6-, 7- or 8-[7H]-purinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 6-, 7- or 8-[7H]-purinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0030] a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-or 9-acridinyl-C₁₋₄ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical can be unsubstituted or mono- or up to octasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0031] a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical can be unsubstituted or mono- or up to octasubstituted by Y;

[0032] a 2-, 3-, 4-, 5- or 6-pyridyl radical, which can be unsubstituted or mono- or up to tetrasubstituted by Y;

[0033] a 2-, 3-, 4-, 5- or 6-pyridinyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 4-, 5- or 6-pyridinyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0034] a 2-, 3-, 4- or 5-thienyl radical, or a 2-, 3-, 4- or 5-thienyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 4- or 5-thienyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0035] a 2-, 4-, or 5-thiazolyl radical, or a 2-, 4-, or 5-thiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, or 5-thiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0036] a 3-, 4-, or 5-isothiazolyl radical, or a 3-, 4-, or 5-isothiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 3-, 4-, or 5-isothiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0037] a 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical, or a 2-, 4-, 5-, 6-, or 7-benzothiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical can be unsubstituted or mono- to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0038] a 1-, 2-, 4-, or 5-imidazolyl radical, or a 1-, 2-, 4-, or 5-imidazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 2-, 4-, or 5-imidazolyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0039] a 1-, 3-, 4-, or 5-pyrazolyl radical, or a 1-, 3-, 4- or 5-pyrazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 3-, 4- or 5-pyrazolyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0040] a 1-, 2-, 3-, 4-, or 5-pyrrolyl radical, or a 1-, 2-, 3-, 4-, or 5-pyrrolyl-C₁₋₆ -alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 2-, 3-, 4- or 5-pyrrolyl radical can be unsubstituted or mono- to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0041] a 1-, 3-, or 5-[1.2.4]-triazolyl radical, or a 1-, 3-, or 5-[1.2.4]-triazolyl -C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 3-, or 5-[1.2.4]-triazolyl radical can be unsubstituted or mono- or disubstituted by Y;

[0042] a 1-, 4-, or 5-[1.2.3]-triazolyl radical, or a 1-, 4-, or 5-[1.2.3]-triazolyl -C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 4-, or 5-[1.2.3]-triazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0043] a 1- or 5-[1H]-tetrazolyl radical, or a 1-, or 5-[1H]-tetrazolyl-(C₁-C₆)-alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, or 5-[1H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y;

[0044] a 2- or 5-[2H]-tetrazoyl radical, or a 2- or 5-[2H]-tetrazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2- or 5-[2H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y;

[0045] a 2-, 4-, or 6-[1.3.5]-triazinyl radical, or a 2-, 4-, or 6-[1.3.5]-triazinyl -C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, or Y;

[0046] a 2-, 4-, or 5-oxazolyl radical, or a 2-, 4-, or 5-oxazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, or 5-oxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0047] a 3-, 4-, or 5-isoxazolyl radical, or a 3-, 4-, or 5-isoxazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 3-, 4-, or 5-isoxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0048] a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical can be unsubstituted or mono- to hexasubstituted by the same or different substituents from the group of hydrogen, or Y, and the isomers, in particular tautomers, diastereomers and enantiomers, and the pharmaceutically acceptable salts, particularly acid addition salts thereof.

[0049] According to a further embodiment of the present invention, pyridine derivatives of formula (1) are provided in which R, R₁, R₂, R₃, X, Z, P, Q, n and m have the meanings given above and R₄ is phenyl which is unsubstituted or substituted by one to five the same or different C₁₋₆ alkoxy groups, wherein adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups.

[0050] According to a further embodiment of the present invention, pyridine derivatives of formula (1) are provided in which R₄ has the meanings given above, R, R₁, R₂, R₃ are each a hydrogen atom, Z is an oxygen atom, X is a nitrogen atom, P and Q each represent two hydrogen atoms as in —CH2—, m is zero and n is 2.

[0051] According to a further embodiment of the present invention, pyridine derivatives of formula (1) are provided in which R, R₁, R₂, R₃, X, Z, P, Q, n and m have the meanings given above, and R₄ is 3,5-dimethoxyphenyl.

[0052] According to yet a further embodiment of the present invention, pyridine derivatives of formula (1) are provided in which R, R₁, R₂, R₃ are each a hydrogen atom, Z is an oxygen atom, X is a nitrogen atom, P and Q are each two hydrogen atoms as in —CH2—, m is zero, n is 2, and R₄ is a 3,5-dimethoxyphenyl radical.

[0053] According to a further aspect of the present invention, a process is provided for preparing pyridine derivatives of formula (1), by reacting a pyridine carboxylic acid of formula (2)

[0054] in which R, R1, R2, R3 have the meanings given above, Z is an oxygen or sulfur atom, and Y represents a leaving group such as halogen, hydroxyl, (C1-C6)-alkoxy, such as methoxy or ethoxy, —O-tosyl, —O-mesyl or imidazolyl, with an amine of formula (3)

[0055] in which R4, X, P, Q, m and n are as defined above, and optionally using diluents and auxiliaries.

[0056] Synthesis Route

[0057] The compounds of formula 1 can be obtained according to the following reaction scheme 1:

[0058] The starting materials of formulae (2) and (3) are either commercially available or can be prepared by procedures known per se. The starting materials of formulae (2) and (3) are useful intermediates for preparing the pyridine derivatives of formula (1) of the present invention.

[0059] The solvents and auxiliaries to be optionally used, and the reaction parameters to be used, such as reaction temperature and reaction time, are known from the literature or are familiar to the person skilled in the art owing to his expert knowledge.

[0060] The pyridine derivatives of formula (1) of the present invention are suitable as medicaments, particularly as antitumor agents, for treating mammals, particularly man, and also domestic animals such as horses, cattle, dogs, cats, rabbits, sheep, poultry and the like.

[0061] According to a further aspect of the invention, a therapeutic method is provided for controlling tumors in mammals, particularly man, by administering at least one pyridine derivative of formula (1) to a mammal in an amount effective for the treatment of the tumor. The therapeutically effective dose of the pyridine derivative according to the invention which is to be administered for the treatment depends inter alia on the nature and the stage of the oncosis, the age and the sex of the patient, the type of administration and the duration of the treatment and can be determined by routine dosage ranging. Administration can take place orally, rectally, buccally (for example sublingually), parenterally (for example subcutaneously, intramuscularly, intradermally or intravenously), topically or transdermally.

[0062] According to a further aspect of the prinvention, medicaments are provided for the treatment of tumors, comprising as active ingredient, at least one pyridine derivative of formulae (1) or a pharmaceutically acceptable salt thereof, optionally together with conventional pharmaceutically acceptable auxiliaries, additives and carriers. These can be solid, semisolid, liquid or aerosol preparations. Suitable solid preparations are, for example, capsules, powders, granules, tablets. Suitable semisolid preparations are, for example, ointments, creams, gels, pastes, suspensions, oil-in-water and water-in-oil emulsions. Suitable liquid preparations are, for example, sterile aqueous preparations for parenteral administration which are isotonic with the blood of the patient.

[0063] The invention is illustrated in more detail by the following example, without being restricted to the example.

1-(3,5-Dimethoxyphenyl)-4-(4-pyridyl-carbonyl)piperazine

[0064] 5 g (45.8 mmol) of pyridine-4-carboxylic acid were suspended with stirring in 150 ml of DMF. With further stirring, 6.93 g (68.5 mmol) of N-methylmorpholine and then a solution of 35.6 g (68.5 mmol) of Py-BOP (1-benzotriazolyltripyrrolidinophosphonium hexafluorophosphate) and 10.18 g (45.8 mmol) of 1-(3,5-dimethoxyphenyl)piperazine in 60 ml of DMF were added to this mixture. The mixture was stirred at room temperature for 24 hours, the DMF was distilled off under reduced pressure and the residue was purified on a silica gel column (Kieselgel 60, from Merck AG, Darmstadt) using the mobile phase dichloromethane/methanol/25 percent ammonia (90:10:1 v/v/v).

[0065] Yield: 12.34 g (82.3% of theory)

[0066] m.p.: 94-96° C. TABLE 1 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 1 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21418 355 2 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21432 397 3 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21464 405 4 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21468 339 HCl-Salz 5 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21466 427 HCl-Salz

[0067] TABLE 2 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 6 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21419 367 7 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21433 397 8 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21465 339 HCl-Salz 9 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21463 463 10 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 21723 505

[0068] TABLE 3 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 11 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 22916 337 12 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 22914 427 13 H H H H N O 2 0 H₂ H₂ 22919 328 14 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 23001 382 15 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 23055 435

[0069] TABLE 4 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 16 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 22915 367 17 H H H H N O 2 0 H₂ H₂ 22920 358 18 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 22918 353 19 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 23195 352 20 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 22917 333

[0070] TABLE 5 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 21 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 24085 362 22 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 24087 338 23 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 24086 338 24 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 24152 415 25 2-Cl H H 6-Cl N O 2 0 H₂ H₂ 24202 377

[0071] TABLE 6 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 26 H H H H N O 2 0 H₂ H₂ 32848 269 27 H H H H N O 2 0 H₂ H₂ 35655 278 28 H H H H N O 2 0 H₂ H₂ 36134 358 29 H H H H N O 2 0 H₂ H₂ 36138 268 30 H H H H N O 2 0 H₂ H₂ 32902 270

[0072] TABLE 7 New Pyridine-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 31 H H H H N O 2 0 H₂ H₂ 35656 296 32 H H H H N O 2 0 H₂ H₂ 41410 310 33 H H H H N O 2 0 H₂ H₂ 41437 365 34 H H H H N O 2 0 H₂ H₂ 41455 326 35 2-OCH₃ H H 6-OCH₃ N O 2 0 H₂ H₂ 24204 388 

We claim:
 1. A pyridine derivative of formula 1

wherein R, R₁, R₂, R₃ can be attached to any of the pyridine carbon atoms C₂ to C₈, and can be the same or different and independently of one another are hydrogen, hydroxyl, straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, straight-chain or branched C₁₋₈ alkylcarbonyl, straight-chain or branched C₁₋₈ alkoxy, halogen, aryl-C₁₋₈ alkoxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, C₁₋₈ alkoxycarbonylamino, C₁₋₆ alkoxycarbonylamino-C₁₋₈ alkyl, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, carboxyl, C₁₋₈ , alkoxycarbonyl, C₁₋₄ alkyl which is substituted by one or more fluorine atoms, carboxy-C₁₋₈ alkyl or C₁₋₈ alkoxycarbonyl-C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, straight-chain or branched cyano-C₁₋₆ alkyl, aryl, where the aryl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of halogen, straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, R and R₁ and/or R₂ and R₃ can form a fused aromatic 6-membered ring with the pyridine ring forming a quinoline or acridine ring which can be substituted at any C atom ring position by the radicals R, R₁, R₂ and R₃ having the meanings mentioned above; Z is oxygen or sulfur, where the radical

 substituted on the pyridine heterocycle can be attached to C atoms C₂₋₆ of the pyridine ring; P,Q are indepedently of one another oxygen or in each case two hydrogen atoms as in —CH₂—; X is nitrogen or C—R₅, where R₅ is hydrogen or a C₁₋₆ alkyl residue; n,m are independently of one another a cardinal number between 0 and 3, with the proviso that when n is 0, X is a CR₅R₆ group where R₅ and R₆ independently of one another are hydrogen or C₁₋₆ alkyl, and that the nitrogen atom adjacent to the C═Z group is substituted by a hydrogen atom or a C₁₋₆ alkyl group; R₄ is a straight-chain or branched C₁₋₂₀ alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or can be substituted at the same or different C atoms by one, two or more aryl, heteroaryl, halogen, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino, cyano, —C═NH (NH₂) or di-C₁₋₄ alkylamino; a C₆₋₁₄ aryl radical, carboxy, C₁₋₄ alkoxycarbonyl, C₆₋₁₄ aryl-C₁₋₄ alkyl radical, or a C₂₋₁₀ heteroaryl, or C₂₋₁₀ heteroaryl-C₁₋₄ alkyl radical which contains one or more heteroatoms of N, O or S, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and where the C₆₋₁₄ aryl or C₂₋₁₀ heteroaryl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl; and their structural isomers and stereoisomers, including tautomers, diastereomers and enantiomers, and their pharmaceutically acceptable salts.
 2. The pyridine derivative of claim 1, wherein in R, R₁, R₂, and R₃, said C₁₋₈ alkylcarbonyl is acetyl, said C₁₋₈ alkoxy is benzyloxy or phenylethoxy, said fluorine atoms are trifluoromethyl, said C₂₋₆ alkenyl is allyl, said C₂₋₆ alkynyl is ethynyl or propargyl, said cyano-C₁₋₆ alkyl is cyanomethyl, said C₁₋₈ alkoxy- carbonyl is tert-butoxycarbonyl, and said C₁₋₈ alkoxy is methoxy or ethoxy, and in R₄ said fluorine atoms are trifluoromethyl, said C₁₋₈ alkoxy is methoxy or ethoxy, and said C₁₋₂ alkylene group is a methylene group.
 3. The pyridine derivative of formula 1 of claim 1, wherein R, R1, R2, R3, P, Q, X, Z, n and m have the meanings given in claim 1 Y is a substituent group of the same or different substituents of C₁₋₆ alkyl, halogen, nitro, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, hydroxyl, C₁₋₆ alkoxy, benzyloxy, carboxyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkyl mono- or polysubstituted with fluorine, C₆₋₁₀ aryl, and C₆₋₁₀ aryl-C₁₋₆ alkyl, and R4 is a straight-chain or branched C₁₋₂₀ alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or substituted on the same or different C atoms by one, two or more aryl, heteroaryl, halogen, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino; a phenyl ring or a naphthyl ring, each of which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl; a 2-, 4-, 5- or 6-pyrimidinyl radical, or a 2-, 4-, 5- or 6-pyrimidinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, 5- or 6-pyrimidinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, 5- or 6-pyridazinyl radical, or a 3-, 4-, 5- or 6-pyridazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 3-, 4-, 5- or 6-pyridazinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 5- or 6-pyrazinyl radical, or a 2-, 3-, 5- or 6-pyrazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 5- or 6-pyrazinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical, or a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical, or a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical, or a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical can be unsubstituted or mono- to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical, or a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O),, and the 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical, or a 2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical can be unsubstituted, or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical, or a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical can be unsubstituted or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 6-, 8- or 9-[9H]-purinyl radical, or a 2-, 6-, 8- or 9-[9H]-purinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 6-, 8- or 9-[9H]-purinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 6-, 7- or 8-[7H]-purinyl radical, or a 2-, 6-, 7- or 8-[7H]-purinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 6-, 7- or 8-[7H]-purinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl-C₁₋₄ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical can be unsubstituted or mono- or up to octasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical can be unsubstituted or mono- or up to octasubstituted by Y; a 2-, 3-, 4-, 5- or 6-pyridyl radical which can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 4-, 5- or 6-pyridyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4-, 5- or 6-pyridinyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 4- or 5-thienyl radical, or a 2-, 3-, 4- or 5-thienyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4- or 5-thienyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, or 5-thiazolyl radical, or a 2-, 4-, or 5-thiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 5-thiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, or 5-isothiazolyl radical, or a 3-, 4-, or 5-isothiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, or 5-isothiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical, or a 2-, 4-, 5-, 6-, or 7-benzothiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical can be unsubstituted or mono- to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 4-, or 5-imidazolyl radical, or a 1-, 2-, 4-, or 5-imidazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 4-, or 5-imidazolyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 3-, 4-, or 5-pyrazolyl radical, or a 1-, 3-, 4- or 5-pyrazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, 4- or 5-pyrazolyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, or 5-pyrrolyl radical, or a 1-, 2-, 3-, 4-, or 5-pyrrolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4- or 5-pyrrolyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 3-, or 5-[1.2.4]-triazolyl radical, or a 1-, 3-, or 5-[1.2.4]-triazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, or 5-[1.2.4]-triazolyl radical can be unsubstituted or mono- or disubstituted by Y; a 1-, 4-, or 5-[1.2.3]-triazolyl radical, or a 1-, 4-, or 5-[1.2.3]-triazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 4-, or 5-[1.2.3]-triazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 1- or 5-[1H]-tetrazolyl radical, or a 1-, or 5-[1H]-tetrazolyl C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, or 5-[1H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y; a 2- or 5-[2H]-tetrazoyl radical, or a 2- or 5-[2H]-tetrazolyl C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2- or 5-[2H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y; a 2-, 4-, or 6-[1.3.5]-triazinyl radical, or a 2-, 4-, or 6-[1.3.5]-triazinyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 6-[1.3.5]-triazinyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, or 5-oxazolyl radical, or a 2-, 4-, or 5-oxazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 5-oxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, or 5-isoxazolyl radical, or a 3-, 4-, or 5-isoxazolyl C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, or 5-isoxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-or 7-indolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical can be unsubstituted or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y.
 4. The pyridine derivative of claim 3, wherein in R₄ said fluorine atoms are trifluoromethyl, and said C₁₋₈ alkoxy is methoxy or ethoxy.
 5. The pyridine derivative of claim 1 wherein R, R₁, R₂, R₃, P, Q, X, Z, n and m have the meanings given above and R4 is phenyl which is unsubstituted or substituted by one or up to five same or different C₁₋₆ alkoxy groups, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups.
 6. The pyridine derivative of claim 1, wherein R, R₁, R₂, R₃, P, Q, X, Z, n and m have the meanings given above and R₄ is 3,5-dimethoxyphenyl.
 7. The pyridine derivative of claim 1, wherein R₄ has the meanings given above, R, R₁, R₂, R₃ each is a hydrogen atom, Z is an oxygen atom, X is a nitrogen atom, P and Q each are two hydrogen atoms as in —CH2—, m is zero, and n is2.
 8. The pyridine derivative of claim 1, wherein R, R₁, R₂, R₃ each are a hydrogen atom, Z is an oxygen atom, X is a nitrogen atom, P and Q each are two hydrogen atoms as in —CH2—, m is zero, n is 2, and R₄ is a 3,5-dimethoxyphenyl radical.
 9. A process for preparing the pyridine derivative of claim 1, which comprises reacting a pyridine carboxylic acid of formula (2)

in which R, R1, R2, R3 have the meanings given above, Z is an oxygen or sulfur atom, and Y is a leaving group with an amine of formula (3)

in which R4, X, P, Q, m and n have the meanings given above, optionally in the presence of diluents and auxiliaries.
 10. The process of claim 10, wherein said leaving group is halogen, hydroxyl, C₁₋₆ alkoxy, —O-tosyl, —O-mesyl, or imidazolyl.
 11. The process of claim 10, wherein said C₁₋₆ alkoxy is methoxy or ethoxy.
 12. A method for treating tumors in mammals, which comprises administering to a mammal in need therefor an antitumor effective amount of at least one pyridine derivative of claim
 1. 13. A drug which comprises as active ingredient at least one pyridine derivative of claim 1, optionally together with a conventional pharmaceutically acceptable auxiliary, additive and carrier. 